Find Capmatinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1029712-80-8, Incb28060, Inc280, Inc-280, Nvp-inc280-nx, Incb-28060
Molecular Formula
C23H17FN6O
Molecular Weight
412.4  g/mol
InChI Key
LIOLIMKSCNQPLV-UHFFFAOYSA-N
FDA UNII
TY34L4F9OZ

Capmatinib
Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
Capmatinib is a Kinase Inhibitor. The mechanism of action of capmatinib is as a Mesenchymal Epithelial Transition Inhibitor, and Cytochrome P450 1A2 Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor, and Multidrug and Toxin Extrusion Transporter 1 Inhibitor, and Multidrug and Toxin Extrusion Transporter 2 K Inhibitor.
1 2D Structure

Capmatinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
2.1.2 InChI
InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
2.1.3 InChI Key
LIOLIMKSCNQPLV-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
2.2 Other Identifiers
2.2.1 UNII
TY34L4F9OZ
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzoic Acid

2. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)-(1,2,4)triazin-2-yl)benzamide

3. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate

4. 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

5. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

6. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide Dihydrochloride

7. Capmatinib Dihydrochloride

8. Capmatinib Dihydrochloride Monohydrate

9. Capmatinib Hydrochloride

10. Capmatinib Hydrochloride Anhydrous

11. Capmatinib Metabolite M13

12. Capmatinib Metabolite M18

13. Cmc-583

14. Cmc583

15. Cnj-294

16. Cnj294

17. Inc-280

18. Inc280

19. Incb-28060

20. Incb-28060 Free Base

21. Incb28060

22. Nvp-inc280

23. Nvp-inc280-nx

24. Tabrecta

2.3.2 Depositor-Supplied Synonyms

1. 1029712-80-8

2. Incb28060

3. Inc280

4. Inc-280

5. Nvp-inc280-nx

6. Incb-28060

7. Nvp-inc280

8. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide

9. Tabrecta

10. Capmatinib (incb28060)

11. Capmatinib [usan]

12. Incb-28060 Free Base

13. Inc28060

14. 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

15. Ty34l4f9oz

16. Incb 28060

17. Benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-

18. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

19. Benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-;benzamide, 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-

20. Capmatinib [inn]

21. Unii-ty34l4f9oz

22. Benzamide Hcl

23. Benzamide, 2-fluoro-n-methyl-4-(7-(6-quinolinylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)-

24. Capmatinib [mi]

25. Capmatinib (usan/inn)

26. Capmatinib [usan:inn]

27. Capmatinib(incb28060)

28. Incb28060(capmatinib)

29. Nyp-inc280-nx

30. Capmatinib [who-dd]

31. Mls006010965

32. Gtpl7904

33. Schembl1426819

34. Chembl3188267

35. Dtxsid90145595

36. Ex-a446

37. Amy18553

38. Bcp23444

39. Bdbm50146167

40. Mfcd18633285

41. Nsc777878

42. Nsc800067

43. S2788

44. Zinc43195321

45. Akos025396439

46. Bcp9000785

47. Ccg-268791

48. Cs-1541

49. Db11791

50. Nsc-777878

51. Nsc-800067

52. Sb16608

53. Ncgc00346702-01

54. Ncgc00346702-02

55. Ncgc00346702-05

56. Ac-25890

57. As-74142

58. Da-33530

59. Hy-13404

60. Smr004702769

61. Ft-0746310

62. D10696

63. J-509516

64. Q27075685

65. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2- Yl)benzamide

66. 2-fluoro-n-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

67. 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazolo[1,2-b][1,2,4]triazin-2-yl]benzamide

68. 2-fluoro-n-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide

2.4 Create Date
2009-02-09
3 Chemical and Physical Properties
Molecular Weight 412.4 g/mol
Molecular Formula C23H17FN6O
XLogP32.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count4
Exact Mass412.14478735 g/mol
Monoisotopic Mass412.14478735 g/mol
Topological Polar Surface Area85.1 Ų
Heavy Atom Count31
Formal Charge0
Complexity637
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.


FDA Label


Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Capmatinib inhibits the overactivity of c-Met, a receptor tyrosine kinase encoded by the _MET_ proto-oncogene. Mutations in _MET_ are involved in the proliferation of many cancers, including non-small cell lung cancer (NSCLC). Capmatinib may cause photosensitivity reactions in patients following ultraviolet (UV) exposure - patients undergoing therapy with capmatinib should be advised to use sunscreen and protective clothing to limit exposure to UV radiation. Instances of interstitial lung disease/pneumonitis, which can be fatal, occurred in patients being treated with capmatinib. Patients presenting with signs or symptoms of lung disease (e.g. cough, dyspnea, fever) should have capmatinib immediately withheld, and capmatinib should be permanently discontinued if no other feasible causes of the lung-related symptoms are identified.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
CAPMATINIB
5.2.2 FDA UNII
TY34L4F9OZ
5.2.3 Pharmacological Classes
Cytochrome P450 1A2 Inhibitors [MoA]; Kinase Inhibitor [EPC]; Mesenchymal Epithelial Transition Inhibitors [MoA]; Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]; Multidrug and Toxin Extrusion Transporter 2 K Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Breast Cancer Resistance Protein Inhibitors [MoA]
5.3 ATC Code

L01EX17


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EX - Other protein kinase inhibitors

L01EX17 - Capmatinib


5.4 Absorption, Distribution and Excretion

Absorption

The oral bioavailability of capmatinib is estimated to be >70%. Following oral administration, maximum plasma concentrations are achieved within 1 to 2 hours (Tmax). Co-administration with a high-fat meal increased capmatinib AUC by 46% with no change in Cmax (as compared to fasted conditions), and co-administration with a low-fat meal had no clinically meaningful effects on exposure.


Route of Elimination

Following oral administration of radiolabeled capmatinib, approximately 78% of the radioactivity is recovered in feces, of which ~42% is unchanged parent drug, and 22% is recovered in the urine, of which a negligible amount remains unchanged parent drug.


Volume of Distribution

The apparent volume of distribution at steady-state is 164 L.


Clearance

The mean apparent clearance of capmatinib at steady-state is 24 L/h.


5.5 Metabolism/Metabolites

Capmatinib undergoes metabolism primarily via CYP3A4 and aldehyde oxidase. Specific biotransformation pathways and metabolic products have yet to be elucidated.


5.6 Biological Half-Life

The elimination half-life is 6.5 hours.


5.7 Mechanism of Action

Aberrant activation of c-Met has been documented in many cancers, including non-small cell lung cancer (NSCLC). Mutations that result in the skipping of _MET_ exon 14 lead to the formation of a mutant c-Met with a missing regulatory domain - these mutant proteins have a reduced ability to negatively regulate, leading to a pathological increase in their downstream activity. Capmatinib inhibits the phosphorylation of both wild-type and mutant variants of c-Met triggered by the binding of its endogenous ligand, hepatocyte growth factor - in doing so, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells.


API SUPPLIERS

read-more
read-more

01

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

02

Shenzhen Haorui

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Biotech Showcase
Not Confirmed
arrow

03

Natco Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Biotech Showcase
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content

Capmatinib

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

02

Natco Pharma

India
BIO Partnering at JPM
Not Confirmed
arrow

Natco Pharma

India
arrow
BIO Partnering at JPM
Not Confirmed

Capmatinib

About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...

NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, NATCO today has five manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.NATCO family currently consists of more than 2500 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. NATCO is well recognized for its innovation in Pharmaceutical R&D.
blank

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Capmatinib

About the Company : Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get...

Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get the domestic registration of their finished dosage for their international expansion. Our USFDA approved products Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, Dasatinib Monohydrate, Oxaliplatin and Temozolomide have been recognized by our customers globally. In addition, our Amisulpride API acquired CEP, UK GMP & USDMF.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649097000,"product":"CAPMATINIB DIHYDROCHLORIDE MONOHYDRATE (FOR R&D PURPOSE)","address":"12TH FLOOR, COMMERZ II,,INTERNATIO NAL BUSNESS PARK,OBEROI","city":"GARDEN CITY OFF WESTERN EXPR HIGHWA","supplier":"TEVA PHARMACEUTICAL INDUSTRIES","supplierCountry":"HUNGARY","foreign_port":"NA","customer":"TEVA PHARMACEUTICAL INDUSTRIES","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"6500","totalValueFC":"7950","currency":"USD","unitRateINR":"599820","date":"05-Apr-2022","totalValueINR":"599820","totalValueInUsd":"7950","indian_port":"BOMBAY AIR","hs_no":"29411090","bill_no":"8143444","productDescription":"API","marketType":"REGULATED MARKET","country":"HUNGARY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"12TH FLOOR, COMMERZ II,,INTERNATIO NAL BUSNESS PARK,OBEROI"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670783400,"product":"CAPMATINIB DIHYDROCHLORIDE HYDRATE","address":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,","city":"HYDERABAD,TELANGANA","supplier":"HANGZHOU PROSERRE CHEMICAL CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"NATCO PHARMA","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"16800","totalValueFC":"16717.2","currency":"USD","unitRateINR":"1377600","date":"12-Dec-2022","totalValueINR":"1377600","totalValueInUsd":"16717.2","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"3708644","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674757800,"product":"CAPMATINIB HCL","address":"12TH FLOOR, COMMERZ II,,INTERNATIO NAL BUSNESS PARK,OBEROI","city":"GARDEN CITY OFF WESTERN EXPR HIGHWA","supplier":"PLIVA HRVATSKA","supplierCountry":"CROATIA","foreign_port":"NA","customer":"TEVA PHARMACEUTICAL INDUSTRIES","customerCountry":"INDIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"4711","totalValueFC":"17071.7","currency":"USD","unitRateINR":"465258.4","date":"27-Jan-2023","totalValueINR":"1395775.08","totalValueInUsd":"17071.7","indian_port":"BOMBAY AIR","hs_no":"29411090","bill_no":"4370593","productDescription":"API","marketType":"REGULATED MARKET","country":"CROATIA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"12TH FLOOR, COMMERZ II,,INTERNATIO NAL BUSNESS PARK,OBEROI"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691605800,"product":"CAPMATINIB DIHYDROCHLORIDE HYDRATE","address":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,","city":"HYDERABAD","supplier":"M S HANGZHOU PROSERRE CHEMICAL CO","supplierCountry":"CHINA","foreign_port":"NA","customer":"NATCO PHARMA","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"17200","totalValueFC":"8661.9","currency":"USD","unitRateINR":"1420693.7","date":"10-Aug-2023","totalValueINR":"717522.08","totalValueInUsd":"8661.9","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,"}]
05-Apr-2022
10-Aug-2023
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

ABOUT THIS PAGE

Capmatinib Manufacturers

A Capmatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Capmatinib, including repackagers and relabelers. The FDA regulates Capmatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Capmatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Capmatinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Capmatinib Suppliers

A Capmatinib supplier is an individual or a company that provides Capmatinib active pharmaceutical ingredient (API) or Capmatinib finished formulations upon request. The Capmatinib suppliers may include Capmatinib API manufacturers, exporters, distributors and traders.

click here to find a list of Capmatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Capmatinib GMP

Capmatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Capmatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Capmatinib GMP manufacturer or Capmatinib GMP API supplier for your needs.

Capmatinib CoA

A Capmatinib CoA (Certificate of Analysis) is a formal document that attests to Capmatinib's compliance with Capmatinib specifications and serves as a tool for batch-level quality control.

Capmatinib CoA mostly includes findings from lab analyses of a specific batch. For each Capmatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Capmatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Capmatinib EP), Capmatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Capmatinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty